Cabrini Health
Industry / private company
Location:
Malvern,
Australia (AU)
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024)
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al.
Journal article
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022)
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al.
Journal article